Mei pharma, inc. (MEIP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'12Mar'12Dec'11Sep'11
Net (loss) income

-

-

-

-

-

-

-

-

-

-

-

-

-602

11,885

-4,270

-

-5,371

-5,101

-4,620

-5,662

-8,930

-9,109

-8,993

-8,541

-7,387

-6,324

-4,896

-

-

-

-

Cash flows from operating activities:
Net loss

-4,329

-20,217

-2,994

3,053

-17,355

12,025

-14,542

-19,253

-5,948

-6,079

-8,788

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,269

-1,541

-1,612

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability

7,732

-8,439

9,269

14,358

-5,201

23,437

-4,962

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation

1,550

1,771

2,113

1,448

1,514

1,663

1,937

749

770

702

996

279

614

674

737

516

639

798

770

493

1,068

1,252

1,410

1,213

1,184

1,174

1,176

122

133

138

118

Gain on adjustment to fair value of derivatives

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

423

716

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

9

397

Depreciation and amortization

30

29

31

28

24

15

13

13

13

13

14

43

13

15

14

13

15

15

15

16

17

15

16

16

10

11

13

3

3

4

3

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

40

429

-300

-718

734

-1,252

2,085

732

82

131

-1,117

-998

88

927

910

-271

315

191

94

-90

59

180

-144

-364

-32

291

146

-397

343

92

-164

Accounts payable

-546

-60

-1,689

2,818

-189

603

-2,088

2,384

170

338

166

343

-140

-367

-330

613

18

195

-610

-1,848

559

1,041

-597

1,008

-109

252

20

153

60

50

3

Accrued liabilities

1,641

728

-1,702

-1,126

919

2,277

-965

1,339

-1,115

463

-18

-426

773

510

-2,005

874

629

56

-1,222

169

-803

533

1,289

90

1,199

711

-230

122

143

81

-87

Deferred revenue

-869

-742

-868

-645

-722

8,401

-48

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-49

-

-

-

15,537

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-10,295

-10,481

-14,078

-8,064

-11,342

2,799

-12,816

-3,483

-6,239

-4,751

-6,562

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,273

-1,774

-1,730

Cash flows from investing activities:
Net cash (used in) provided by operating activities

-

-

-

-

-

-

-

-

-

-

-

-

1,606

-3,747

8,773

-

-4,385

-4,228

-5,761

-6,742

-8,148

-6,448

-6,731

-5,850

-5,071

-4,467

-4,063

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

49

0

0

2

-

-

-

-

-

-

-

-

29

16

-1

6

-

-

-

-

Purchases of short-term investments

20,125

50,220

19,979

24,899

19,986

14,833

4,937

84,296

14,899

10,039

4,999

10,013

20,030

10,026

20,054

15,048

5,018

15,047

20,125

5,014

10,035

50,030

4,998

-

-

-

-

-

-

-

-

Proceeds from maturity of short-term investments

30,008

14,909

24,946

34,864

29,789

14,812

9,725

24,866

19,997

15,002

10,041

10,022

15,018

15,034

10,023

15,078

10,023

15,073

25,040

10,012

15,031

20,000

14,993

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

9,103

-35,316

4,967

9,955

9,768

-193

4,788

-59,430

5,098

4,963

5,042

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-5,012

5,008

-10,033

-

5,002

26

4,915

4,999

4,990

-30,040

9,995

-38

-15,022

-20,000

-6

-

-

-

-

Proceeds from exercise of stock options

0

0

72

53

252

24

43

140

0

169

20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

0

0

0

1,118

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-8

48,451

159

-

-

-

-

-

-

-

-

-

0

0

4,212

-

-

-

-

-

-

-

-

-

-

-

-

4,784

4

1,974

3,069

Collection of common stock proceeds receivable

0

0

5,274

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of RSU tax withholdings in exchange for

-

-

-

0

0

0

324

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

9

397

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4,212

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-8

48,451

5,505

273

252

24

837

70,024

0

169

20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

1,965

2,672

Net decrease in cash and cash equivalents

-1,200

2,654

-3,606

-

-1,322

2,630

-7,191

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

7,111

-1,141

381

-1,500

-3,186

-3,406

1,261

2,952

-3,454

617

-4,202

-846

-1,743

-3,192

6,616

3,264

-5,893

-20,092

8,258

-4,069

3,480

-2,269

191

942

Supplemental cash flow information:
Income taxes paid

0

0

-1

0

0

0

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-